Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Army
Cantor Fitzgerald
Accenture
Daiichi Sankyo
Express Scripts

Generated: August 22, 2019

DrugPatentWatch Database Preview

ASTELLAS Company Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for ASTELLAS
International Patents:406
US Patents:31
Tradenames:18
Ingredients:14
NDAs:33
Patent Litigation for ASTELLAS: See patent lawsuits for ASTELLAS

Drugs and US Patents for ASTELLAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes 7,144,872 ➤ Sign Up Y Y ➤ Sign Up
Astellas ADENOSCAN adenosine SOLUTION;INTRAVENOUS 020059-001 May 18, 1995 DISCN Yes No ➤ Sign Up ➤ Sign Up
Astellas XOSPATA gilteritinib fumarate TABLET;ORAL 211349-001 Nov 28, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up
Astellas ASTAGRAF XL tacrolimus CAPSULE, EXTENDED RELEASE;ORAL 204096-001 Jul 19, 2013 RX Yes No 6,576,259 ➤ Sign Up Y ➤ Sign Up
Astellas CRESEMBA isavuconazonium sulfate CAPSULE;ORAL 207500-001 Mar 6, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes 8,470,801 ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for ASTELLAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas CYCLOCORT amcinonide OINTMENT;TOPICAL 018498-001 Approved Prior to Jan 1, 1982 4,158,055 ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 8,133,879 ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 7,183,264 ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 9,289,446 ➤ Sign Up
Astellas MYCAMINE micafungin sodium INJECTABLE;INTRAVENOUS 021506-002 Mar 16, 2005 6,265,536 ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 8,470,801 ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 0.08 mg/mL, 5 mL vial ➤ Subscribe 2012-04-10
➤ Subscribe Extended-release Capsules 0.5 mg, 1 mg, and 5 mg ➤ Subscribe 2013-11-15
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 2014-06-16
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-16
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2009-04-08
➤ Subscribe Capsules 40 mg ➤ Subscribe 2016-08-31
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 2005-04-18

Supplementary Protection Certificates for ASTELLAS Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0788511 91452 Luxembourg ➤ Sign Up 91452, EXPIRES: 20200929
1189916 392 Finland ➤ Sign Up
0801067 CA 2004 00037 Denmark ➤ Sign Up
1189916 CA 2011 00005 Denmark ➤ Sign Up PRODUCT NAME: REGADENOSON OG SALTE DERAF
1189916 91785 Luxembourg ➤ Sign Up 91785, EXPIRES: 20250621
1280795 92939 Luxembourg ➤ Sign Up PRODUCT NAME: ISAVUCONBAZOLE EN TANT QUE SULFATE D'ISAVUCONAZONIUM OU EN TANT QUE SEL D'ISAVUCONAZONIUM AVEC TOUT AUTRE ANION PHARMACEUTIQUEMENT ACCEPTABLE, OPTIONNELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; FIRST REGISTRATION: 20151019
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Julphar
Chinese Patent Office
Mallinckrodt
US Department of Justice
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.